Plus Therapeutics, Inc. (PSTV)

NASDAQ: PSTV · IEX Real-Time Price · USD
0.445
-0.035 (-7.29%)
At close: Sep 30, 2022 4:00 PM
0.470
+0.025 (5.62%)
After-hours: Sep 30, 2022 7:44 PM EDT
-7.29%
Market Cap 14.49M
Revenue (ttm) n/a
Net Income (ttm) -17.28M
Shares Out 32.57M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 313,447
Open 0.466
Previous Close 0.480
Day's Range 0.440 - 0.480
52-Week Range 0.390 - 2.160
Beta 0.11
Analysts Buy
Price Target 3.57 (+702.2%)
Earnings Date Oct 19, 2022

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori T... [Read more...]

Industry Biotechnology
Founded 1996
CEO Marc Hedrick
Employees 14
Stock Exchange NASDAQ
Ticker Symbol PSTV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 702.25% from the latest price.

Price Target
$3.57
(702.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022

1 week ago - GlobeNewsWire

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical ...

Phase 1 data indicates that direct administration of 186 RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma

2 weeks ago - GlobeNewsWire

Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult...

3 weeks ago - GlobeNewsWire

Plus Therapeutics Announces Summary of FDA Meeting on Company's cGMP Manufacturing Process for Lead Drug Candidate

cGMP production of 186 RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials

1 month ago - GlobeNewsWire

Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congr...

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

1 month ago - GlobeNewsWire

Why Is Plus Therapeutics (PSTV) Stock Up 56% Today?

Source: CI Photos / Shutterstock.com Plus Therapeutics (NASDAQ: PSTV ) stock is in the news Thursday as investors react to the company getting a $17.6 million grant. That Product Development Research gr...

1 month ago - InvestorPlace

Plus Therapeutics Awarded $17.6 Million from State of Texas

Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186 RNL for ...

1 month ago - GlobeNewsWire

Why Is Plus Therapeutics (PSTV) Stock Up 38% Today?

Source: Shutterstock / PopTika Plus Therapeutics (NASDAQ: PSTV ) stock is climbing higher on Monday after the company revealed a stock buyback program. According to a press release from the company, its...

1 month ago - InvestorPlace

Plus Therapeutics Announces Share Repurchase Program

AUSTIN, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-...

1 month ago - GlobeNewsWire

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinic...

AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

1 month ago - GlobeNewsWire

Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Tria...

AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

2 months ago - GlobeNewsWire

Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

2 months ago - GlobeNewsWire

Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for Leptomeningeal Metastases

2 months ago - GlobeNewsWire

Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022

AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

2 months ago - GlobeNewsWire

Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic

Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome ( 186 RNL) drug product intermediate

2 months ago - GlobeNewsWire

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

Biocept's CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system

3 months ago - GlobeNewsWire

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort

3 months ago - GlobeNewsWire

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Mo...

Data validates continued high radiation absorbed of 186 RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure

3 months ago - GlobeNewsWire

Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference

AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-t...

4 months ago - GlobeNewsWire

3 Stocks Under $1 Insiders Are Aggressively Buying

US crude oil futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: CRTDLVO
5 months ago - Benzinga

Plus Therapeutics to Present at the 2022 Q2 Investor Summit

AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult...

5 months ago - GlobeNewsWire

Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases

5 months ago - GlobeNewsWire

Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 A...

AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

5 months ago - GlobeNewsWire

Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022

AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

5 months ago - GlobeNewsWire

Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

5 months ago - GlobeNewsWire